Treatment strategies for ocular toxicity from chloropicrin

氯化苦眼部毒性的治疗策略

基本信息

  • 批准号:
    10463565
  • 负责人:
  • 金额:
    $ 23.48万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2021
  • 资助国家:
    美国
  • 起止时间:
    2021-09-01 至 2024-08-31
  • 项目状态:
    已结题

项目摘要

Project Summary Chloropicrin (Trichloronitromethane, CP), currently used as a soil fumigant and pesticide, was employed during World War I as a tear gas and choking agent and remains a potential agent for chemical terrorism. Its exposure causes severe ocular injury, especially to the corneal tissue; however, mechanisms of its injury are not well-defined and effective targeted treatments are elusive. The major goal of this application is to identify a novel targeted therapeutic approach, which can effectively mitigate acute and long-term ocular injuries from CP exposure, with a potential to be further tested against ocular injuries from other toxic chemical exposures. Data from our studies in corneal epithelial cells and ex vivo rabbit cornea demonstrate increased levels of nuclear erythroid 2-related factor 2 (Nrf2) and heme oxygenase-1 (HO-1), a critical target enzyme downstream of Nrf2, suggesting that the Nrf2 pathway, a key antioxidant and cytoprotective system, could be activated following CP exposure. Under this application, we propose to further asses the role of the Nrf2 pathway under CP-induced ocular injury using Nrf2 knockout (KO) mice. Nrf2 activity triggers cellular protective mechanisms against oxidative stress and inflammatory responses and is reported as a key target of new approaches for treating various oxidative stress-related ocular diseases/injuries. Hence, employing Nrf2 activators may be a novel approach for the treatment of ocular injuries due to CP exposure. Chemical ocular injury causes hypoxia that leads to tissue damage; oxygen therapy is reported to improve tissue preservation and enhance wound healing to mitigate ocular chemical and thermal burns. Our preliminary data shows the therapeutic potential of supersaturated oxygen emulsion (SSOE) therapy in reversing CP-induced acute toxicity in HCE cells and ex vivo rabbit corneas. Our hypothesis is that the Nrf2 signaling pathway is a key mediator in protecting against CP-induced corneal injury; activation of the Nrf2 pathway can inhibit CP-induced oxidative stress and inflammation, and simultaneous treatment with SSOE can increase tissue oxygen levels to improve tissue preservation and enhance wound healing, leading to a novel and more effective treatment strategy against CP- induced acute and long-term ocular injury. To test this hypothesis, the proposed aims are: Aim 1. To develop a CP-induced ocular injury model in mice and determine if the Nrf2-ARE pathway is a key mediator in CP- induced ocular injury using wild type and Nrf2 KO mice. Aim 2. To evaluate the efficacy of Nrf2 activators and supersaturated oxygen emulsion alone, or in combination, to identify an effective therapeutic strategy against CP-induced ocular injury. We anticipate that the outcomes from the above aims will establish a useful mouse ocular injury model with CP and ascertain if the Nrf2 signaling pathway is a novel target for therapeutic intervention to counteract CP-induced ocular injury. Successful completion of this project will identify a novel therapeutic approach that can more effectively mitigate acute and chronic ocular injuries from CP and lead to a better understanding of the mechanisms of CP-induced ocular toxicity.
项目总结

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Neera Tewari-Singh其他文献

Neera Tewari-Singh的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Neera Tewari-Singh', 18)}}的其他基金

Treatment strategies for ocular toxicity from chloropicrin
氯化苦眼部毒性的治疗策略
  • 批准号:
    10853300
  • 财政年份:
    2021
  • 资助金额:
    $ 23.48万
  • 项目类别:
Treatment strategies for ocular toxicity from chloropicrin
氯化苦眼部毒性的治疗策略
  • 批准号:
    10206886
  • 财政年份:
    2021
  • 资助金额:
    $ 23.48万
  • 项目类别:
Targeted Therapeutic Approaches to Counteract Toxicity from Phosgene Oxime Skin Exposure
抵消光气肟皮肤暴露毒性的靶向治疗方法
  • 批准号:
    10252890
  • 财政年份:
    2019
  • 资助金额:
    $ 23.48万
  • 项目类别:
Targeted Therapeutic Approaches to Counteract Toxicity from Phosgene Oxime Skin Exposure
抵消光气肟皮肤暴露毒性的靶向治疗方法
  • 批准号:
    10013129
  • 财政年份:
    2019
  • 资助金额:
    $ 23.48万
  • 项目类别:
Phosgene Oxime Cutaneous Toxicity and Mechanisms to Identify Therapeutic Targets
光气肟皮肤毒性和识别治疗靶点的机制
  • 批准号:
    9420148
  • 财政年份:
    2017
  • 资助金额:
    $ 23.48万
  • 项目类别:

相似海外基金

Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
  • 批准号:
    MR/X02329X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 23.48万
  • 项目类别:
    Fellowship
Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
  • 批准号:
    MR/Y009568/1
  • 财政年份:
    2024
  • 资助金额:
    $ 23.48万
  • 项目类别:
    Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
  • 批准号:
    10090332
  • 财政年份:
    2024
  • 资助金额:
    $ 23.48万
  • 项目类别:
    Collaborative R&D
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
  • 批准号:
    MR/X021882/1
  • 财政年份:
    2024
  • 资助金额:
    $ 23.48万
  • 项目类别:
    Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
  • 批准号:
    MR/X029557/1
  • 财政年份:
    2024
  • 资助金额:
    $ 23.48万
  • 项目类别:
    Research Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
  • 批准号:
    EP/Y003527/1
  • 财政年份:
    2024
  • 资助金额:
    $ 23.48万
  • 项目类别:
    Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
  • 批准号:
    EP/Y030338/1
  • 财政年份:
    2024
  • 资助金额:
    $ 23.48万
  • 项目类别:
    Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
  • 批准号:
    2312694
  • 财政年份:
    2024
  • 资助金额:
    $ 23.48万
  • 项目类别:
    Standard Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
  • 批准号:
    24K19395
  • 财政年份:
    2024
  • 资助金额:
    $ 23.48万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Collaborative Research: Changes and Impact of Right Ventricle Viscoelasticity Under Acute Stress and Chronic Pulmonary Hypertension
合作研究:急性应激和慢性肺动脉高压下右心室粘弹性的变化和影响
  • 批准号:
    2244994
  • 财政年份:
    2023
  • 资助金额:
    $ 23.48万
  • 项目类别:
    Standard Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了